Skip to main content

SciClone Surges on Trial Data

The stock jumps more than 40%.

Shares of

SciClone Pharmaceuticals


were soaring Friday after the company and its partner Sigma-Tau announced positive results from an early trial of the drug Zadaxin in skin cancer.

Scroll to Continue

TheStreet Recommends

Patients who received the drug plus dacarbazine chemotherapy survived a median 10.2 months, while patients on dacarbazine and the common treatment interferon alpha survived roughly 6.6 months.

The trial involved 386 patients with stage IV melanoma, the most advanced form of skin cancer, in which the disease has spread to other parts of the body.

Lately, SciClone was climbing $1, or 44%, to $3.26 in extremely heavy volume.

Additionally, those receiving Zadaxin were about twice as likely to experience significant tumor shrinkage, supporting previously reported interim trial results, SciClone says.